DDInter1825 DDInter1657
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod